TP53 and ovarian carcinoma: This result agrees with previous studies on smaller cohorts (Kohler et al, 1993; Buttitta et al, 1997; Reles et al, 2001; Leitao et al, 2002), which have shown a TP53 mutation rate in early-stage ovarian cancer between 15 and 50%.